Bristol-Myers Squibb Company





Market Closed - Nyse 04:00:08 2024-05-17 pm EDT 5-day change 1st Jan Change
44.01 USD -0.23% Intraday chart for Bristol-Myers Squibb Company -2.07% -14.23%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Everlasting momentum Our Logo
Bristol Myers Gets FDA OK of Breyanzi in Follicular Lymphoma DJ
Bristol-Myers Squibb Gets FDA Accelerated Approval for Breyanzi for Follicular Lymphoma MT
Bristol Myers Squibb's CAR T Cell Therapy Breyanzi Approves by the U.S. Food and Drug Administration for Relapsed or Refractory Follicular Lymphoma CI
US FDA approves expanded use of Bristol's cancer cell therapy RE
Transcript : Bristol-Myers Squibb Company Presents at Bank of America Health Care Conference 2024, May-15-2024 11:20 AM
Transcript : Bristol-Myers Squibb Company Presents at Guggenheim Securities Radiopharmaceuticals Day, May-13-2024 11:00 AM
Bristol-Myers Squibb Says Phase 3 Trial of Opdivo in Lung Cancer Fails to Meet Primary Endpoint MT
Bristol Myers Squibb Cancer-Treatment Trial Misses Endpoint DJ
Bristol Myers Squibb Provides Update on Phase 3 CheckMate -73L Trial CI
India's Cipla open to partnering with Eli Lilly to market their obesity drugs, CEO says RE
Declaration of Voting Results by Bristol-Myers Squibb Company CI
Declaration of Voting Results by Bristol-Myers Squibb Company CI
India's Alembic Pharma posts higher Q4 profit on strong N.America sales RE
Ligand Pharmaceuticals Investing in Agenus to Fund Development of Oncology Drug Candidates MT
Top Midday Stories: Tyson Shares Tumble on Earnings Miss; Robinhood Receives Wells Notice From SEC Staff; Spirit Airlines to Furlough up to 260 Pilots; Shell in Talks to Sell Malaysian Gas Station Business to Saudi Aramco MT
Bristol-Myers Squibb Says Applications for Opdivo Accepted by US, European Regulators MT
Bristol-Myers Gets FDA Acceptance of Review for Subcutaneous Opdivo Formulation DJ
Bristol-Myers: BLA accepted for subcutaneous Opdivo CF
U.S. Food and Drug Administration Accepts Bristol Myers Squibb?s Application for Subcutaneous Nivolumab (nivolumab and hyaluronidase) CI
European Medicines Agency Validates Bristol Myers Squibb?s Application for Opdivo Plus Yervoy for the First-Line Treatment of Adult Patients with Microsatellite Instability?High or Mismatch Repair Deficient Metastatic Colorectal Cancer CI
HSBC Adjusts Price Target on Bristol-Myers Squibb to $45 From $50 MT
Editas Medicine, Bristol-Myers Squibb Extend Alpha-Beta T Cell Collaboration MT
Editas Medicine and Bristol Myers Squibb Extend Alpha-Beta T Cell Collaboration CI
Global markets live: Adidas, Mercedes, McDonalds, Eli Lilly, PayPal, MicroStrategy, Tesla... Our Logo
Chart Bristol-Myers Squibb Company
More charts
Bristol-Myers Squibb Company est spécialisé dans le développement, la fabrication et la commercialisation de produits pharmaceutiques. Les produits sont destinés au traitement des cancers, des maladies cardio-vasculaires, de l'hépatite, des maladies immunitaires et des désordres psychiatriques. The United States account for 70.1% of net sales.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Mean consensus
Number of Analysts
Last Close Price
44.03 USD
Average target price
53.19 USD
Spread / Average Target
  1. Stock Market
  2. Equities
  3. BMY Stock
  4. News Bristol-Myers Squibb Company
  5. Wells Fargo Adjusts Bristol-Myers Squibb's Price Target to $52 From $51, Keeps Equalweight Rating
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.